Target Atlas of Apoptopic Drugs & Focus on Lung Cancer & Melanoma

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

• 3.1 List of Tables
• 3.2 List of Boxes
• 3.3 List of Figures

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

• 6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

• 7.1 Expression in Normal Tissues and Cancer Tissues
• 7.2 Expression in Human Cancer Cell Lines and Primary Cells

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

• 11.1.1 Auxiliary transport protein activity
• 11.1.2 Carboxy-lyase activity
• 11.1.3 Catalytic activity
• 11.1.4 Cell adhesion molecule activity
• 11.1.5 Chaperone activity
• 11.1.6 Complement activity
• 11.1.7 Cysteine-type peptidase activity
• 11.1.8 Cytokine activity
• 11.1.9 DNA topoisomerase activity
• 11.1.10 Glutathione transferase activity
• 11.1.11 Hormone activity
• 11.1.12 Hydrolase activity
• 11.1.13 Intracellular ligand-gated ion channel activity
• 11.1.14 Kinase activity
• 11.1.15 Kinase regulator activity
• 11.1.16 Ligase activity
• 11.1.17 Lipid kinase activity
• 11.1.18 Metallopeptidase activity
• 11.1.19 Molecular function unknown
• 11.1.20 Motor activity
• 11.1.21 Oxidoreductase activity
• 11.1.22 Peptide hormone
• 11.1.23 Peroxidase activity
• 11.1.24 Protein binding
• 11.1.25 Protein serine/threonine kinase activity
• 11.1.26 Protein threonine/tyrosine kinase activity
• 11.1.27 Protein-tyrosine kinase activity
• 11.1.28 Receptor activity
• 11.1.29 Receptor binding
• 11.1.30 Receptor signaling complex scaffold activity
• 11.1.31 Receptor signaling protein serine/threonine kinase activity
• 11.1.32 RNA binding
• 11.1.33 Structural constituent of cytoskeleton
• 11.1.34 Superoxide dismutase activity
• 11.1.35 T cell receptor activity
• 11.1.36 Transcription factor activity
• 11.1.37 Transcription regulator activity
• 11.1.38 Transferase activity
• 11.1.39 Translation regulator activity
• 11.1.40 Transmembrane receptor activity
• 11.1.41 Transmembrane receptor protein tyrosine kinase activity
• 11.1.42 Transporter activity

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

• 13.1 Basal Cell Cancer
• 13.2 Biliary Cancer
• 13.3 Bladder Cancer
• 13.4 Bone Cancer
• 13.5 Brain Cancer
• 13.6 Breast Cancer
• 13.7 Carcinoid Tumor
• 13.8 Cervical Cancer
• 13.9 Chemotherapy-induced Neutropenia
• 13.10 Colorectal Cancer
• 13.11 Endometrial Cancer
• 13.12 Fallopian Tube Cancer
• 13.13 Gastrointestinal Cancer
  • 13.13.1 Gastrointestinal Stomach Cancer
  • 13.13.2 Gastrointestinal Stromal Cancer
• 13.14 Head and Neck Cancer
• 13.15 Leukemia
  • 13.15.1 Acute Lymphocytic Leukemia
  • 13.15.2 Acute Myelogenous Leukemia
  • 13.15.3 Chronic Lymphocytic Leukemia
  • 13.15.4 Chronic Myelogenous Leukemia
• 13.16 Liver Cancer
• 13.17 Lung Cancer
  • 13.17.1 Non-Small Cell Lung Cancer
  • 13.17.2 Small Cell Lung Cancer
• 13.18 Lymphoma
  • 13.18.1 B-cell Lymphoma
  • 13.18.2 Hodgkin' s Lymphoma
  • 13.18.3 non-Hodgkin' s Lymphoma
  • 13.18.4 T-cell Lymphoma
• 13.19 Melanoma
• 13.20 Mesothelioma
• 13.21 Myelodysplastic Syndrome
• 13.22 Myeloma
• 13.23 Nasopharyngeal Cancer
• 13.24 Oesophageal Cancer
• 13.25 Oral Cancer
• 13.26 Ovarian Cancer
• 13.27 Pancreatic Cancer
• 13.28 Peritoneal Cancer
• 13.29 Prostate Cancer
• 13.30 Renal Cancer
• 13.31 Sarcoma
  • 13.31.1 Leiomyo Sarcoma
• 13.32 Squamous Cell Cancer
• 13.33 Testicular Cancer
• 13.34 Thymoma Cancer
• 13.35 Thyroid Cancer

14 Apoptopic Drugs and their Targets by Companies

• 14.1 Australia
• 14.2 Canada
• 14.3 China
• 14.4 Denmark
• 14.5 Germany
• 14.6 Israel
• 14.7 Japan
• 14.8 South Korea
• 14.9 Spain
• 14.10 Switzerland
• 14.11 Taiwan
• 14.12 United Kingdom
• 14.13 USA

15 Lung cancer: An Introduction

• 15.1 Current Treatment Strategies
• 15.2 Disease Definition
• 15.3 Etiology & Pathophysiology
• 15.4 Prognosis
• 15.5 Epidemiology

16 Progress in Current Lung Cancer Treatment Strategies

• 16.1 Improvements Adding microtubule Inhibitor
• 16.2 Improvement of Disease Related Symptoms in Elderly Patients
• 16.3 Toxicity Profile Favored
• 16.4 A New Formula
• 16.5 Monotherapy?
• 16.6 Failed to Demonstrate a Survival Advantage
• 16.7 Reduction in Mortality Risk

17 Key Drug Strategies in Lung Cancer

• 17.1 Apoptosis
• 17.2 Antiangiogenesis and Antivascular Agents
  • 17.2.1 EGFR and VEGFR as target
  • 17.2.2 Immunotherapy

18 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

• 18.1 Grade 4 Adverse Events
• 18.2 No New Remarks
• 18.3 No Significant Effect on Overall Survival
• 18.4 Bristol Myers Squibb Entered into an Agreement
• 18.5 Many Uncertainties Remain
• 18.6 Development Terminated
• 18.7 Continuing Enrollment
• 18.8 Apoptotic Inducer
• 18.9 Fully-Human Monoclonal Antibody
• 18.10 Eagerly Awaiting Data
• 18.11 Mutations and Response
• 18.12 Statistically and Clinically Significant Survival Advantage
• 18.13 Anti-Idiotypic Monoclonal Antibody
• 18.14 Shift in the Development Focus
• 18.15 Sensitizer
• 18.16 Treatment in Earlier-Stage Cancer Could be More Effective
• 18.17 Discontinued Radiosensitizer
• 18.18 Improvement in Chemoradiotherapy
• 18.19 Progress on HDAC Inhibitor
• 18.20 Progress Analysis Carboxyamidotriazole
• 18.21 Chemotherapy naïve subjects

19 Etiology and Pathophysiology of Melanoma

20 Current Melanoma Treatment Strategies

• 20.1 An Overview
• 20.2 Cytotoxic Drugs
  • 20.2.1 Dacarbazine
  • 20.2.2 Cisplatin
  • 20.2.3 Carboplatin
  • 20.2.4 Carmustine
  • 20.2.5 Melphalan
  • 20.2.6 Paclitaxel
  • 20.2.7 Tamoxifen
  • 20.2.8 Temozolomide
  • 20.2.9 Vinblastine/Vinorelbine
• 20.3 Biological treatments
  • 20.3.1 Intron A
  • 20.3.2 Virulizin
  • 20.3.3 Melacine
  • 20.3.4 Alfanative (Multiferon)
  • 20.3.5 Proleukin or (Macrolin)
  • 20.3.6 Enhanzyn
  • 20.3.7 M-VAX
• 20.4 Other
  • 20.4.1 Ceplene Maxamine

21 Key Melanoma Therapy Strategies

• 21.1 Immunotherapy
• 21.2 Anti-angiogenesis
• 21.3 Apoptotic Induction
• 21.4 Gene Therapy

22 Current Melanoma Drug Development: Late Stage Pipeline

• 22.1 Immunotherapy
  • 22.1.1 Oncophage
  • 22.1.2 Canvaxin
  • 22.1.3 GMK
  • 22.1.4 MDX-010
  • 22.1.5 OncoVax
  • 22.1.6 ALLOVECTIN-7
  • 22.1.7 Peginterferon alfa-2b
• 22.2 Anti-angiogenesis
  • 22.2.1 Lenalidomide
• 22.3 Apoptotic Inducers
  • 22.3.1 Genasense
• 22.4 Inhibiting Cell Growth
  • 22.4.1 Temozolomide

23 Current Melanoma Drug Development: Early Stage Pipeline

• 23.1 Immunotherapy
  • 23.1.1 INGN 241
  • 23.1.2 QS-21
  • 23.1.3 Talabostat
  • 23.1.4 SB 249553
  • 23.1.5 GVAX
  • 23.1.6 GV 1001
  • 23.1.7 Dexosome
  • 23.1.8 Uvidem
  • 23.1.9 NY-ESO-1 ISCOMS
  • 23.1.10 NOVOVAC-M1
  • 23.1.11 Oxxon Vaccine
  • 23.1.12 Therion' s Melanoma Vaccine
  • 23.1.13 ImmunoVex trimelan
  • 23.1.14 OncoVEXGM-CSF
  • 23.1.15 Zadaxin
  • 23.1.16 Alvac-Mage1/Mage3
  • 23.1.17 Iboctadekin
  • 23.1.18 ProMune
  • 23.1.19 BAY 504798
  • 23.1.20 EMD 273063
• 23.2 Antiangiogenesis
  • 23.2.1 Sorafenib
  • 23.2.2 Vitaxin
  • 23.2.3 Avastin
  • 23.2.4 PI 88
• 23.3 Apoptotic Inducers
  • 23.3.1 Didemnin B
  • 23.3.2 KOS 953
• 23.4 Small Molecules Inhibiting Cell Growth
  • 23.4.1 Pivanex
  • 23.4.2 Karenitecin
  • 23.4.3 Lomeguatrib
  • 23.4.4 PD 0325901
  • 23.4.5 SB 715992
  • 23.4.6 INO 1001
  • 23.4.7 CP 4055
• 23.5 Other Biological Drugs
  • 23.5.1 AP 12009
  • 23.5.2 Ecromeximab
  • 23.5.3 ILX 651
  • 23.5.4 Kahalalide F
  • 23.5.5 ABX MA1
  • 23.5.6 MJV 101
  • 23.5.7 A Russian Melanoma Vaccine
  • 23.5.8 Elea Vaccine
  • 23.5.9 F 50040

24 Appendix 1. Treatment Guide Lines Lung Cancer*

• 24.1 References

25 Appendix 2: Selected Company Profiles

• 25.1 Abgenix
• 25.2 Aphton
• 25.3 AstraZeneca
• 25.4 Bristol-Myers Squibb
• 25.5 Eli Lilly
• 25.6 Genentech
• 25.7 Genta
• 25.8 GlaxoSmithKline
• 25.9 ImClone
• 25.10 ISIS Pharmaceuticals
• 25.11 Ligand Pharmaceuticals
• 25.12 OSI Pharmaceuticals
• 25.13 Pfizer
• 25.14 Pharmacyclics
• 25.15 Sanofi- Aventis
• 25.16 Telik

26 Appendix 3 Progress profiles on approved drugs

• 26.1 Docetaxel
• 26.2 Vinorelbine
• 26.3 Gemcitabine
• 26.4 Paclitaxel
• 26.5 Pemetrexed
• 26.6 Gefitinib
• 26.7 Erlotinib

27 Appendix 4: Treatment Guide Lines Melanoma

28 Disclaimer

29 Drug Index

30 Company Index

List of Tables

• Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
• Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs
• Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
• Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs
• Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
• Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
• Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets
• Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets
• Table 13: Number of Available Biological Structures on Apoptopic Drug Targets
• Table 14: Overview of Drug Target Profile Themes
• Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage
• Table 16: Apoptopic Drug Target Mixes by Development
• Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication
• Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
• Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
• Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
• Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
• Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
• Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
• Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type Developmental Stage of Drug
• Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to the Compound Type and Developmental Stage of Drug
• Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
• Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
• Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
• Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
• Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug
• Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
• Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug
• Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug
• Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
• Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
• Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
• Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
• Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug
• Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
• Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
• Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
• Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug
• Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
• Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug
• Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug
• Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
• Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia
• Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada
• Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China
• Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark
• Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany
• Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel
• Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan
• Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain
• Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland
• Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan
• Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom
• Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA
• Table 64: Chemotherapeutic drugs for treatment of NSCLC
• Table 65. Near Term Approved Drugs for the Treatment of NSCLC
• Table 66: Chemotherapy Drugs off Patent
• Table 67: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
• Table 68: VTA agents under development
• Table 69: EGFR or VEGFR inhibitors
• Table 70: FMS-like tyrosine kinases and their Synonyms
• Table 71: Fms-related Tyrosine Kinase Targets in Development
• Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 73: Cancer immunotherapy strategies
• Table 74: Recently presented studies Lapatinib
• Table 75: Recently presented studies ZD-6474
• Table 76: Recently presented studies vinflunine
• Table 77: Recently presented studies Panitumumab
• Table 78: Recently presented studies Genasense
• Table 79: Recently presented studies cetuximab
• Table 80: Recently presented studies bevacizumab
• Table 81: Recently presented studies bexarotene
• Table 82: Recently presented studies Xcytrin
• Table 83: Critical Risk Factors for Development of Melanoma
• Table 84: Definition and Description of Stages of Melanoma
• Table 85: Prognosis of the 4 Stages of Malignant Melanoma
• Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma
• Table 87: Progress Profile Dacarbazine
• Table 88: Progress Profile Cisplatin
• Table 89: Progress Profile Carboplatin
• Table 90: Progress Profile Carmustine
• Table 91: Progress Profile Melphalan
• Table 92: Progress Profile Paclitaxel
• Table 93: Progress Profile Tamoxifen
• Table 94: Progress Profile Temozolomide
• Table 95: Progress Profile Vinblastine/Vinorelbine
• Table 96: Progress Profile Interferon alfa-2b
• Table 97: Development Milestones- Virulizin
• Table 98: Development Milestones - Melacine
• Table 99: Development Milestones - Alfanative
• Table 100: Development Milestones - Proleukin
• Table 101: Deployed Strategies for Blocking Angiogenesis
• Table 102: Phase III Randomized Studies of Melanoma Vaccines.
• Table 103: Tumor antigen based vaccines
• Table 104: In vivo Gene Therapy
• Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
• Table 106: Ex vivo gene therapy loading of antigen presenting cells
• Table 107: Overview of Immunostimulants in Development based on Type
• Table 108: Overview of Immuno-Biologicals
• Table 109: Overview of Gene Therapy Drugs for Immunostimulation
• Table 110: MDX-010' s Collaborative History and Landscape
• Table 111: Anti-angiogenisis Drugs under Development
• Table 112: Overview Apoptopic Inducer Drugs
• Table 113: Overview of Small Molecule Drugs
• Table 114: Selected Regulatory Progress of Sorafenib
• Table 115: Selected Regulatory Progress of Didemin B
• Table 116: Overview of Various Biological Drugs in Development for Melanoma

List of Boxes

• Box 1: Quick facts on Docetaxel
• Box 2: Scientific Data on Docetaxel
• Box 3: Quick Facts - Vinorelbine
• Box 4: Scientific Data on Vinorelbine
• Box 5: Quick Facts - Gemcitabine
• Box 6: Scientific Data on gemcitabine
• Box 7: Quick Facts - pemetrexed
• Box 8: Scientific Data on Pemetrexed
• Box 9: Quick Facts - Gefitinib
• Box 10: Scientific Data on Gefitinib
• Box 11: Quick Facts - Erlotinib
• Box 12: Quick Facts - Enhanzyn
• Box 13: Quick Facts - M-VAX
• Box 14: M-VAX - Business & Market Bakground
• Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction
• Box 16: Introgen' s INGN 241 Shows Vaccine Properties
• Box 17: Quick Facts - Oncophage
• Box 18: Oncophage - Designation and Status
• Box 19: Quick Facts - Canvaxin
• Box 20: Canvaxin - Designation and Status
• Box 21: CancerVax Milestone payment
• Box 22: Quick Facts - GM2-KLH Vaccine
• Box 23: Progenics Reaquires Rights to Vaccine
• Box 24: Completed Melanoma Phase III trials
• Box 25: Quick Facts - MDX-010
• Box 26: Quick Facts -OncoVax
• Box 27: Quick Facts - ALLOVECTIN-7
• Box 28: Quick Facts - Peginterferon alfa-2b
• Box 29: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
• Box 30: Quick Facts - Lenalidomide
• Box 31: Quick Facts - Oblimersen
• Box 32: Quick Facts - Temozomide
• Box 33: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
• Box 34: Regulatory Progress
• Box 35: Quick Facts - INGN 241
• Box 36: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
• Box 37: Quick Facts - QS-21
• Box 38: Quick Facts - Talabostat
• Box 39: Quick Facts - SB 249553
• Box 40: Quick Facts - GVAX
• Box 41: Agreement Japan Tobacco and Cell Genesys
• Box 42: Predicted launch of GVAX
• Box 43: Quick Facts - GV 1001
• Box 44: Quick Facts - Dexosome
• Box 45: Important Milestones and License Fees
• Box 46: Quick Facts - Uvidem
• Box 47: Agreements Between Sanofi-Aventis and IDM
• Box 48: Quick Facts - NY-ESO-1 ISCOMS
• Box 49: NY-ESO-1 and ISCOMATRIX
• Box 50: Quick Facts - NovoVac-M1
• Box 51: Quick Facts - Oxxon vaccine
• Box 52: Quick Facts - Therion' s Melanoma Vaccine
• Box 53: Quick Facts - ImmunoVEX trimelan
• Box 54: Quick Facts - OncoVEX GM-CSF
• Box 55: Quick Facts - ZADAXIN
• Box 56: Developmental History Thymosin alpha1
• Box 57: Quick Facts - Alvac-Mage1/Mage3
• Box 58: Quick Facts - iboctadekin
• Box 59: Quick Facts - PF-3512676
• Box 60: Quick Facts - BAY-504798
• Box 61: Quick Facts - EMD-273063
• Box 62: Quick Facts - Sorefenib
• Box 63: Quick Facts - Vitaxin
• Box 64: Quick Facts . Bevacizumab
• Box 65: Quick Facts - PI88
• Box 66: Quick Facts - Didemnin B
• Box 67: Quick Facts - KOS 953
• Box 68: Quick Facts - Pivanex
• Box 69: Quick Facts - Karenitecin
• Box 70: Company Statement
• Box 71: Quick Facts - Lomeguatrib

List of Figures

• Box 72: Quick Facts - PD 0325901
• Box 73: Quick Facts - SB 715992
• Box 74: Quick Facts - INO 1001
• Box 75: Quick Facts - CP 4055
• Box 76: Quick Facts - AP 12009
• Box 77: Quick Facts - Ecromeximab
• Box 78: Quick Facts - ILX 651
• Box 79: Quick Facts - Kahalalide F
• Box 80: Quick Facts - ABX MA1
• Box 81: Quick Facts - MJV 101
• Box 82: Quick Facts - Russian Melanoma Vaccine
• Box 83: Quick Facts - N-Acetyl-GM3 ganglioside
• Box 84: Quick Facts - F 50040
• Box 85: KpOmpA Technology

List of Figures

• Figure 1: Distribution of Compound Types Among Apoptopic Drugs
• Figure 2: Primary Sub-cellular Localization of Drug Targets